CSLLY Stock UPDATES Csl Limited (CSLLY) 34.4000 08/30/2014 0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Csl Limited (CSLLY) 34.4000 $CSLLY

Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014: Espy the Commercial Landscape of the Major Universities / Institutes / Hospitals & Companies
M2 - Fri Aug 15, 4:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2fqtrx/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering. "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Harvard Pilgrim Health Care, Inc. - GlaxoSmithKline plc - CSL Limited Clinical Trial Overview of Top Institutes / Government - Erasmus MC - FDA Office of Orphan Products Development - Chhatrapati Shahuji Maharaj Medical University - Mansoura University - University Medical Centre Ljubljana - University of Versailles - University of Cologne - NHS Greater Glasgow and Clyde - National Taiwan University Hospital For more information visit http://www.researchandmarkets.com/research/2f...llainbarre

Global Blood Plasma Market Report: 2014 Edition
M2 - Fri Jul 11, 8:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v86kh7/global_blood) has announced the addition of the "Global Blood Plasma Market Report: 2014 Edition" report to their offering. With the swift changes and advancement in biomedical/healthcare technology, the healthcare/pharmaceutical/therapeutic industry is becoming ever more competitive. Also, increasing incidences of health related issues owing to changing lifestyles is augmenting the blood plasma industry's growth. In order to address the rising medical needs related to blood disorders such as autoimmune diseases and liver function impairment among others, market players are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma. The blood plasma industry is highly regulated to ensure the safety of collected plasma and protect donors. The market is characterized by fast pace developments in the clinical technology and testing methodology. The report, Global Blood Plasma Market presents different facets of the global blood plasma market with a focus on sub-markets like IVIG, albumin and hemophilia market. Moreover, market dynamics like the key trends, industry developments, growth drivers and challenges are analyzed in detail. Furthermore, the competitive landscape of the industry is presented. The market remains highly concentrated and is dominated by a handful of players including CSL, Grifols, Baxter and Octapharma. The profiles of these leading players are also included in the report along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. Blood Plasma Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Baxter International Inc. - CSL Limited - Grifols - Octapharma AG For more information visit http://www.researchandmarkets.com/research/v8...obal_blood

Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Clinical Trials Review, H1, 2014
M2 - Tue Jul 08, 9:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6tm85/chronic) has announced the addition of the "Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" report to their offering. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Clinical Trials Review, H1, 2014" provides data on the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - CSL Limited - LFB S.A. - Biogen Idec Inc. - Takeda Pharmaceutical Company Limited - Octapharma AG - Novartis AG - Kedrion S.p.A. - Grifols, S.A. - Grifols Deutschland Gmbh - GeNeuro SA - National Center for Research Resources - Aarhus University - Erasmus MC - State University of New York at Buffalo - Stony Brook University - University of Cologne - Northwestern University - Centre Hospitalier Universitaire de Saint Etienne - Oregon Health and Science University - Rigshospitalet For more information visit http://www.researchandmarkets.com/research/n6tm85/chronic




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 54

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 141

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
Thanksgiving in Outer Banks: Unique Traditions Await

Updated Category News Views 115

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

Continue Reading
AI Deception Challenges the Confidence of Fraud Defenses

Updated Category News Views 145

Fraud Week Spotlights AI Deception Alright, here's the rub: we're in Fraud Week 2026, and boy, is AI shaking the foundations of yesterday's fraud defenses! With all this AI talk, you would expect systems to be near invincible by now. But reality? A different beast altogether. AI has this knack of tripling up the complexity while pretending to solve it, making traditional...

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 85

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
FiEE Rockets to Profitability with 382% Revenue Surge

Updated Category News Views 188

Big Moves in the Tech Jungle: FiEE's Comeback Let's chew the fat on FiEE, Inc., a company that's left its hardware-heavy past in the dust and grabbed the bull by the horns with fresh, AI-driven brand tech solutions. We're talking a whopping 382.1% revenue increase. Now, that's not chump change. From barely scraping $2 million last year to raking in $9.6 million just for...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 50

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Koppers Faces SEC Scrutiny After Earnings Miss

Updated Category News Views 182

Koppers' Third-Quarter Blues: Missing the Mark Koppers Holdings Inc. (NYSE: KOP) took a hard hit this quarter, missing Wall Street's earnings expectations by a mile. The adjusted earnings per share came in at just $0.77, while the suits down on Wall Street were expecting something closer to $1.34 to $1.37. Now, if you’re holding KOP in your portfolio, you're probably...

Continue Reading
Terra Kaffe's Big Win with Oprah's Endorsement

Updated Category News Views 109

Terra Kaffe Hits the Jackpot with Oprah Sometimes, destiny has a way of handing out golden tickets, and for Terra Kaffe, receiving a nod from Oprah Winfrey's revered list of Favorite Things for 2026 is nothing short of that. I mean, you can't underestimate the pull Mrs. O has. Her endorsement isn’t just another celebrity pat-on-the-back, it’s a megaphone blaring...

Continue Reading

Top 5 Most Recently Viewed Articles

INSEAD's MIM Programme Achieves Strong Global Recognition

Updated Category News Views 207

INSEAD Master in Management Rankings Achievements INSEAD, known as the Business School for the World, has made a remarkable debut in the Financial Times Master in Management (MIM) Ranking, achieving an impressive #3 position globally among 100 distinguished institutions. This noteworthy entry highlights the strong quality and worldwide appeal of the INSEAD MIM programme....

Continue Reading
Jumptuit Achieves New Milestone with AI Patent for Enhanced Search

Updated Category News Views 642

Jumptuit's Innovative AI Search Patent Jumptuit proudly announces its recent achievement in securing a new patent from the U.S. Patent and Trademark Office (USPTO). Inventor Donald Leka, who is also the Founder and CEO of Jumptuit, has successfully obtained the patent titled "SYSTEM AND METHOD OF AI ASSISTED SEARCH." This development represents a significant leap in the...

Continue Reading
Lead Developer Highlights Value of Dogecoin Amid Industry Challenges

Updated Category News Views 69

Dogecoin's Unique Role in the Crypto World Dogecoin is frequently labeled as a meme coin, but it encompasses a significance that distinguishes it from many other cryptocurrencies. This viewpoint comes from its lead developer, who passionately defends Dogecoin’s value in a challenging and unpredictable market. Perspectives from the Lead Developer of Dogecoin Recently,...

Continue Reading
AMD Teams Up with US Department of Energy for Major AI Project

Updated Category News Views 174

AMD's Strategic Partnership with the U.S. Department of Energy On a recent episode of CNBC’s ‘Mad Money’ show, Jim Cramer, the well-known host, expressed his excitement over a substantial victory for Advanced Micro Devices Inc. (NASDAQ: AMD). The company has established a transformative partnership with the U.S. Department of Energy, worth a staggering $1 billion....

Continue Reading
Visionary Holdings Inc. Drives Governance Forward at AGM

Updated Category News Views 317

Reinventing Governance: Visionary Holdings Inc. Concludes AGM Toronto is buzzing with excitement following the successful conclusion of Visionary Holdings Inc.'s Annual General Meeting (AGM), a pivotal event in the company's calendar. This online gathering, held via Zoom, was a chance for stakeholders to witness significant corporate developments that promise to steer the...

Continue Reading